1
|
Xie Y, Wang X, Lan Y, Xu X, Shi S, Yang Z, Li H, Han J, Liu Y. Assessment of radiation knowledge among medical personnel in nuclear emergency preparedness: a cross-sectional study. Front Public Health 2025; 13:1547818. [PMID: 40078773 PMCID: PMC11899641 DOI: 10.3389/fpubh.2025.1547818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2024] [Accepted: 02/13/2025] [Indexed: 03/14/2025] Open
Abstract
Background Radiation literacy, encompassing the understanding of basic principles, applications, risks, and protective measures related to ionizing radiation, is critical for medical personnel working in jobs that involve the use of radioactive materials or medical imaging. In the context of nuclear emergency preparedness, the level of radiation knowledge among healthcare professionals-such as doctors, nurses, and radiographers-directly influences the effectiveness and safety of emergency responses. This study aims to address this gap by evaluating the radiation knowledge of medical personnel and identifying areas for improvement in profession-specific training programs. Methods A cross-sectional study was conducted using a convenience sampling method. The study included 723 participants attending a medical emergency response exercise and clinical management workshop on radiation injury in Suzhou, China, in November 2023. Data were collected through a structured questionnaire, descriptive statistics and chi-square tests were performed to analyze participants' radiation knowledge and identify variations across different professional groups. Results The majority of participants were female (64.73%), married (75.10%), and held an undergraduate degree (69.99%). Nurses (40.11%) and clinical doctors (30.29%) constituted the largest professional groups. Significant disparities in radiation knowledge were observed among healthcare workers. Nurses and management personnel demonstrated a stronger grasp of fundamental radiation concepts, such as radioactive nuclides and absorbed doses, compared to clinical doctors. For instance, 85.52% of nursing personnel and 72.34% of management personnel accurately identified the half-life of iodine-131, while only 49.32% of clinical doctors showed comparable knowledge. Furthermore, substantial differences in radiation emergency response capabilities were noted across professions. These findings emphasize the necessity for tailored, profession-specific training programs in radiation protection and emergency preparedness. Conclusion The study reveals a generally insufficient understanding of basic radiation concepts and emergency response principles among medical personnel. Significant variations in radiation knowledge were observed across different professional groups, highlighting the need for specialized training modules. These modules should focus on fundamental radiation concepts, radiation exposure effects, and emergency response protocols, with content customized to address the unique needs of each professional group. By implementing such targeted training, the overall effectiveness and safety of nuclear emergency responses can be significantly enhanced.
Collapse
Affiliation(s)
- Yanjun Xie
- The Second Afffliated Hospital of Soochow University, Suzhou, China
- Global Health Institute, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
- Department of Occupational and Environmental Health, School of Public Health, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
| | - Xining Wang
- The Second Afffliated Hospital of Soochow University, Suzhou, China
- Global Health Institute, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
- Department of Occupational and Environmental Health, School of Public Health, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
| | - Yuemin Lan
- The Second Afffliated Hospital of Soochow University, Suzhou, China
- State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, China
| | - Xinyu Xu
- Global Health Institute, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
- Department of Occupational and Environmental Health, School of Public Health, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
| | - Shaoteng Shi
- Global Health Institute, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
- Department of Occupational and Environmental Health, School of Public Health, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
| | - Zhihao Yang
- Global Health Institute, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
- Department of Occupational and Environmental Health, School of Public Health, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
| | - Hongqiu Li
- Global Health Institute, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
- Department of Occupational and Environmental Health, School of Public Health, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
| | - Jing Han
- Global Health Institute, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
- Department of Occupational and Environmental Health, School of Public Health, Health Science Center, Xi’an Jiaotong University, Xi’an, Shaanxi, China
| | - Yulong Liu
- The Second Afffliated Hospital of Soochow University, Suzhou, China
- State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, China
| |
Collapse
|
2
|
Song Y, Wang Y, Wang W, Xie Y, Zhang J, Liu J, Jin Q, Wu W, Li H, Wang J, Zhang L, Yang Y, Gao T, Xie M. Advancements in noninvasive techniques for transplant rejection: from biomarker detection to molecular imaging. J Transl Med 2025; 23:147. [PMID: 39901268 PMCID: PMC11792214 DOI: 10.1186/s12967-024-05964-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2024] [Accepted: 12/11/2024] [Indexed: 02/05/2025] Open
Abstract
Transplant rejection remains a significant barrier to the long-term success of organ transplantation. Biopsy, although considered the gold standard, is invasive, costly, and unsuitable for routine monitoring. Traditional biomarkers, such as creatinine and troponin, offer limited predictive value owing to their low specificity, and conventional imaging techniques often fail to detect early organ damage, increasing the risk of undiagnosed rejection episodes. Considering these limitations, emerging noninvasive biomarkers and molecular imaging techniques hold promise for the early and accurate detection of transplant rejection, enabling personalized management strategies. This review highlights noninvasive biomarkers that predict, diagnose, and assess transplant prognosis by reflecting graft injury, inflammation, and immune responses. For example, donor-derived cell-free DNA (dd-cfDNA) is highly sensitive in detecting early graft injury, whereas gene expression profiling effectively excludes moderate-to-severe acute rejection (AR). Additionally, microRNA (miRNA) profiling enhances the diagnostic specificity for precise AR detection. Advanced molecular imaging techniques further augment the monitoring of rejection. Fluorescence imaging provides a high spatiotemporal resolution for AR grading, ultrasound offers real-time and portable monitoring, and magnetic resonance delivers high tissue contrast for anatomical assessments. Nuclear imaging modalities such as single photon emission computed tomography and positron emission tomography, enable dynamic visualization of immune responses within transplanted organs. Notably, dd-cfDNA and nuclear medicine imaging have already been integrated into clinical practice, thereby demonstrating the translational potential of these techniques. Unlike previous reviews, this work uniquely synthesizes advancements in both noninvasive biomarkers and molecular imaging, emphasizing their complementary strengths. Biomarkers deliver molecular-level insights, whereas imaging provides spatial and temporal resolution. Together, they create a synergistic framework for comprehensive and precise transplant monitoring. By bridging these domains, this review underscores their individual contributions and collective potential to enhance diagnostic accuracy, improve patient outcomes, and guide future research and clinical applications in transplant medicine.
Collapse
Affiliation(s)
- Yuan Song
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Yihui Wang
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Wenyuan Wang
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Yuji Xie
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Junmin Zhang
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Jing Liu
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Qiaofeng Jin
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Wenqian Wu
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - He Li
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Jing Wang
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Li Zhang
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
- Shenzhen Huazhong University of Science and Technology Research Institute, Shenzhen, 518029, China
| | - Yali Yang
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China.
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China.
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
| | - Tang Gao
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China.
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China.
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
| | - Mingxing Xie
- Department of Ultrasound Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 JieFang Avenue, Wuhan, 430022, China.
- Clinical Research Center for Medical Imaging in Hubei Province, Wuhan, 430022, China.
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
- Shenzhen Huazhong University of Science and Technology Research Institute, Shenzhen, 518029, China.
| |
Collapse
|
3
|
Schildt A, Sänger P, Lütgens M, Polei S, Lappe C, Joksch M, Krause BJ, Vollmar B, Weber MA, Lindner T. Radiation protection and personal dosimetry in a core facility for multimodal small animal imaging. ROFO-FORTSCHR RONTG 2024. [PMID: 39631739 DOI: 10.1055/a-2462-2419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2024]
Abstract
Clinical imaging techniques such as positron emission tomography (PET) in combination with computed tomography (CT) are increasingly being used in biomedical research involving small animal models. The handling of open radioactive substances (radiopharmaceuticals) necessary for PET imaging requires prior official authorization for handling, the application of radiation protection principles, and regular training. The overriding aim of radiation protection is to protect the personnel directly involved, other persons, and the environment from the harmful effects of ionizing radiation.This paper aims to provide an overview of the regulatory requirements of the Radiation Protection Act (StrlSchG), the Radiation Protection Ordinance (StrlSchV), and the associated standards and guidelines. Furthermore, their implementation in practical work in small animal imaging using PET/CT is shown. We will focus on the individual steps of the imaging process, from delivery of the radiopharmaceuticals to waste disposal. This should provide interested researchers with an initial overview of the safe and successful use of the method. In addition, exposure values from the last six years in the literature were analyzed. While personal dosimetric monitoring in clinical PET/CT imaging has been extensively published, there is no published data known to us for personnel for PET/CT research with small animals. The evaluation of the personal dosimetric monitoring of our small animal imaging facility with 7 employees over 4 years revealed an increased personal and finger dose normalized to the injected activity and compared to human PET/CT imaging. Nevertheless, the annual personal dose or annual finger dose in small animal imaging (Hp(10): 1.7 mSv, Hp(0.07): 64 mSv) is lower than for personnel performing human PET/CT imaging at the local University Department of Nuclear Medicine (Hp(10): 3.8 mSv, Hp(0.07): 156 mSv) or published values, and is well below the legally permissible maximum dose of 20 or 500 mSv per year.The increasing use of PET/CT in small animal research can be safely utilized if the radiation protection principles are implemented and continuously trained. · PET/CT imaging in small animals is increasingly used in biomedical research.. · Radiation protection laws and guidelines have to be known and are relevant in animal experiments.. · Compared to published values from human medicine, activity-specific employee doses are increased in the presented imaging facility.. · The legal personal dose in the studied imaging facility is below legal limits.. · Schildt A, Sänger P, Lütgens M et al. Radiation protection and personal dosimetry in a core facility for multimodal small animal imaging. Fortschr Röntgenstr 2024; DOI 10.1055/a-2462-2419.
Collapse
Affiliation(s)
- Anna Schildt
- Core Facility Multimodal Small Animal Imaging, Rostock University Medical Center, Rostock, Germany
| | - Peter Sänger
- Radiation Protection Office, Rostock University Medical Center, Rostock, Germany
| | - Matthias Lütgens
- Radiation Protection Office, Rostock University Medical Center, Rostock, Germany
- Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, Rostock University Medical Center, Rostock, Germany
| | - Stefan Polei
- Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, Rostock University Medical Center, Rostock, Germany
| | - Chris Lappe
- Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, Rostock University Medical Center, Rostock, Germany
| | - Markus Joksch
- Core Facility Multimodal Small Animal Imaging, Rostock University Medical Center, Rostock, Germany
| | - Bernd Joachim Krause
- Core Facility Multimodal Small Animal Imaging, Rostock University Medical Center, Rostock, Germany
- Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany
| | - Brigitte Vollmar
- Core Facility Multimodal Small Animal Imaging, Rostock University Medical Center, Rostock, Germany
- Rudolf-Zenker-Institute for Experimental Surgery, Rostock University Medical Center, Rostock, Germany
| | - Marc-André Weber
- Core Facility Multimodal Small Animal Imaging, Rostock University Medical Center, Rostock, Germany
- Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, Rostock University Medical Center, Rostock, Germany
| | - Tobias Lindner
- Core Facility Multimodal Small Animal Imaging, Rostock University Medical Center, Rostock, Germany
- Institute of Diagnostic and Interventional Radiology, Pediatric Radiology and Neuroradiology, Rostock University Medical Center, Rostock, Germany
| |
Collapse
|
4
|
Tan H, Gu Y, Xiu Y, Han X, Wen Q, Lv Z, Fan W, Li S, Tan J, Wang F, Fu W, Zhang Y, Xin J, Ouyang W, Wang X, Liu B, Chen Y, Liu X, Mo Y, Luo Q, Wang J, Li M, Di Y, Xu T, Shi H. Recombinant Human Thyrotropin Plus Radioactive Iodine Among Patients With Thyroid Cancer: A Noninferiority Randomized Clinical Trial. JAMA Netw Open 2024; 7:e2443407. [PMID: 39509132 PMCID: PMC11544486 DOI: 10.1001/jamanetworkopen.2024.43407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2024] [Accepted: 09/13/2024] [Indexed: 11/15/2024] Open
Abstract
Importance Radioactive iodine (131I or RAI) therapy has long been the standard of care for most patients with differentiated thyroid cancer (DTC) after primary surgery. However, no multicenter prospective studies have identified the optimal administered activity and stimulation method for RAI therapy in patients with intermediate-risk DTC. Objective To compare the efficacy and safety of recombinant human thyrotropin (SNA001) with thyroid hormone withdrawal (THW) plus 3.7 GBq RAI in patients with intermediate-risk DTC. Design, Setting, and Participants This noninferiority, open-label, phase 3 randomized clinical trial was conducted at 19 sites in China from April 16, 2020, to September 9, 2021, with a follow-up period of 8 months. Patients aged 18 to 70 years with DTC who had undergone a total or near-total thyroidectomy and had no distant metastasis were enrolled in the trial. Statistical analysis followed the full analysis and per-protocol analysis sets and was performed between November 18, 2021, and April 18, 2022. Intervention Patients were randomly assigned 1:1 to receive SNA001, 0.9 mg, intramuscular injection daily for 2 days or to undergo thyroid hormone withdrawal for 3 to 6 weeks. Main Outcomes and Measures The primary end point was the success rate after 6 to 8 months of RAI therapy. Success was defined as a negative diagnostic whole-body scan result and a stimulated thyroglobulin level less than 1.0 ng/mL. Results A total of 307 patients (192 females [62.5%]; median [range] age, 40 [19-69] years) were randomized: 154 to the SNA001 group and 153 to the THW group. Baseline characteristics were evenly matched between the 2 groups. Noninferiority in the success rate of RAI therapy between groups was met, with success rates of 43.8% in the SNA001 group and 47.1% in the THW group (risk difference, -3.3; 95% CI, -14.8 to 8.3 percentage points). Forty-six patients (29.9%) in the SNA001 group reported adverse events compared with 90 (58.8%) in the THW group during RAI therapy (P < .001). No treatment-related adverse events leading to discontinuation and drug modification occurred in the SNA001 group. Conclusions and Relevance This randomized clinical trial showed that SNA001 was noninferior to THW plus 3.7 GBq RAI in patients with predominantly intermediate-risk DTC. SNA001 also demonstrated a favorable safety profile compared with THW and had a lower incidence of adverse events. Trial Registration Chinese Clinical Trial Registry Identifier: ChiCTR2100046907.
Collapse
Affiliation(s)
- Hui Tan
- Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Yushen Gu
- Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Yan Xiu
- Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Xingmin Han
- Department of Nuclear Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Qiang Wen
- Department of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Zhongwei Lv
- Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Shanghai, China
| | - Wei Fan
- Department of Nuclear Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China
| | - Sijin Li
- Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China
| | - Jian Tan
- Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China
| | - Feng Wang
- Department of Nuclear Medicine, Nanjing First Hospital, Nanjing, China
| | - Wei Fu
- Department of Nuclear Medicine, Guilin Medical University Affiliated Hospital, Guilin, China
| | - Yifan Zhang
- Department of Nuclear Medicine, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China
| | - Jun Xin
- Department of Nuclear Medicine, Shengjing Hospital of China Medical University, Shenyang, China
| | - Wei Ouyang
- Department of Nuclear Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China
| | - Xuemei Wang
- Department of Nuclear Medicine, Affiliated Hospital of Inner Mongolia Medical College, Huhehaote, China
| | - Bin Liu
- Department of Nuclear Medicine, Sichuan University West China Hospital, Chengdu, China
| | - Yue Chen
- Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University, Luzhou, China
| | - Xuegong Liu
- Department of Nuclear Medicine, Anhui Provincial Hospital, Hefei, China
| | - Yi Mo
- Department of Nuclear Medicine, Hunan Cancer Hospital, Changsha, China
| | - Quanyong Luo
- Department of Nuclear Medicine, Shanghai 6th People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
| | - Jing Wang
- Department of Nuclear Medicine, Xijing Hospital of Airforce Medical University, Xian, China
| | - Meng Li
- Department of Clinical Medicine, SmartNuclide Biopharma Co Ltd, Suzhou, China
| | - Yan Di
- Department of Clinical Medicine, SmartNuclide Biopharma Co Ltd, Suzhou, China
| | - Tao Xu
- Department of Clinical Medicine, SmartNuclide Biopharma Co Ltd, Suzhou, China
| | - Hongcheng Shi
- Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China
| |
Collapse
|
5
|
Hourtovenko C, Sreetharan S, Tharmalingam S, Tai TC. Impact of Ionizing Radiation Exposure on Placental Function and Implications for Fetal Programming. Int J Mol Sci 2024; 25:9862. [PMID: 39337351 PMCID: PMC11432287 DOI: 10.3390/ijms25189862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2024] [Revised: 08/19/2024] [Accepted: 09/10/2024] [Indexed: 09/30/2024] Open
Abstract
Accidental exposure to high-dose radiation while pregnant has shown significant negative effects on the developing fetus. One fetal organ which has been studied is the placenta. The placenta performs all essential functions for fetal development, including nutrition, respiration, waste excretion, endocrine communication, and immunological functions. Improper placental development can lead to complications during pregnancy, as well as the occurrence of intrauterine growth-restricted (IUGR) offspring. IUGR is one of the leading indicators of fetal programming, classified as an improper uterine environment leading to the predisposition of diseases within the offspring. With numerous studies examining fetal programming, there remains a significant gap in understanding the placenta's role in irradiation-induced fetal programming. This review aims to synthesize current knowledge on how irradiation affects placental function to guide future research directions. This review provides a comprehensive overview of placental biology, including its development, structure, and function, and summarizes the placenta's role in fetal programming, with a focus on the impact of radiation on placental biology. Taken together, this review demonstrates that fetal radiation exposure causes placental degradation and immune function dysregulation. Given the placenta's crucial role in fetal development, understanding its impact on irradiation-induced IUGR is essential.
Collapse
Affiliation(s)
- Cameron Hourtovenko
- Medical Sciences Division, NOSM University, 935 Ramsey Lake Rd., Sudbury, ON P3E 2C6, Canada
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Rd., Sudbury, ON P3E 2C6, Canada
| | - Shayen Sreetharan
- Medical Sciences Division, NOSM University, 935 Ramsey Lake Rd., Sudbury, ON P3E 2C6, Canada
- Department of Medical Imaging, London Health Sciences Centre, 339 Windermere Rd., London, ON N6A 5A5, Canada
| | - Sujeenthar Tharmalingam
- Medical Sciences Division, NOSM University, 935 Ramsey Lake Rd., Sudbury, ON P3E 2C6, Canada
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Rd., Sudbury, ON P3E 2C6, Canada
| | - T C Tai
- Medical Sciences Division, NOSM University, 935 Ramsey Lake Rd., Sudbury, ON P3E 2C6, Canada
- School of Natural Sciences, Laurentian University, 935 Ramsey Lake Rd., Sudbury, ON P3E 2C6, Canada
| |
Collapse
|
6
|
Struelens L, Huet C, Broggio D, Dabin J, Desorgher L, Giussani A, Li WB, Nosske D, Lee YK, Cunha L, Carapinha MJR, Medvedec M, Covens P. Joint EURADOS-EANM initiative for an advanced computational framework for the assessment of external dose rates from nuclear medicine patients. EJNMMI Phys 2024; 11:38. [PMID: 38647987 PMCID: PMC11035505 DOI: 10.1186/s40658-024-00638-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Accepted: 03/28/2024] [Indexed: 04/25/2024] Open
Abstract
BACKGROUND In order to ensure adequate radiation protection of critical groups such as staff, caregivers and the general public coming into proximity of nuclear medicine (NM) patients, it is necessary to consider the impact of the radiation emitted by the patients during their stay at the hospital or after leaving the hospital. Current risk assessments are based on ambient dose rate measurements in a single position at a specified distance from the patient and carried out at several time points after administration of the radiopharmaceutical to estimate the whole-body retention. The limitations of such an approach are addressed in this study by developing and validating a more advanced computational dosimetry approach using Monte Carlo (MC) simulations in combination with flexible and realistic computational phantoms and time activity distribution curves from reference biokinetic models. RESULTS Measurements of the ambient dose rate equivalent Ḣ*(10) at 1 m from the NM patient have been successfully compared against MC simulations with 5 different codes using the ICRP adult reference computational voxel phantoms, for typical clinical procedures with 99mTc-HDP/MDP, 18FDG and Na131I. All measurement data fall in the 95% confidence intervals, determined for the average simulated results. Moreover, the different MC codes (MCNP-X, PHITS, GATE, GEANT4, TRIPOLI-4®) have been compared for a more realistic scenario where the effective dose rate Ė of an exposed individual was determined in positions facing and aside the patient model at 30 cm, 50 cm and 100 cm. The variation between codes was lower than 8% for all the radiopharmaceuticals at 1 m, and varied from 5 to 16% for the face-to face and side-by-side configuration at 30 cm and 50 cm. A sensitivity study on the influence of patient model morphology demonstrated that the relative standard deviation of Ḣ*(10) at 1 m for the range of included patient models remained under 16% for time points up to 120 min post administration. CONCLUSIONS The validated computational approach will be further used for the evaluation of effective dose rates per unit administered activity for a variety of close-contact configurations and a range of radiopharmaceuticals as part of risk assessment studies. Together with the choice of appropriate dose constraints this would facilitate the setting of release criteria and patient restrictions.
Collapse
Affiliation(s)
- Lara Struelens
- Belgian Nuclear Research Center (SCK CEN), Nuclear Medical Applications, Boeretang 200, 2400, Mol, Belgium.
| | - Christelle Huet
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SDOS, 31 Avenue de La Division Leclerc, 92260, Fontenay-Aux-Roses, France
| | - David Broggio
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PSE-SANTE/SDOS, 31 Avenue de La Division Leclerc, 92260, Fontenay-Aux-Roses, France
| | - Jérémie Dabin
- Belgian Nuclear Research Center (SCK CEN), Nuclear Medical Applications, Boeretang 200, 2400, Mol, Belgium
| | - Laurent Desorgher
- Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Augusto Giussani
- Federal Office for Radiation Protection (BfS), Ingolstädter Landstr. 1, 85764, Oberschleißheim, Germany
| | - Wei Bo Li
- Federal Office for Radiation Protection (BfS), Ingolstädter Landstr. 1, 85764, Oberschleißheim, Germany
| | - Dietmar Nosske
- Federal Office for Radiation Protection (BfS), Ingolstädter Landstr. 1, 85764, Oberschleißheim, Germany
| | - Yi-Kang Lee
- Université Paris-Saclay, CEA, Service d'études des réacteurs et de mathématiques appliquées, 91191, Gif-Sur-Yvette, France
| | - Lidia Cunha
- Nuclear Medicine and Molecular Imaging, IsoPor-Azores, Canada do Breado, 9700, Angra Do Heroismo, Azores, Portugal
| | - Maria J R Carapinha
- ESTeSL-Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisboa, Portugal
| | - Mario Medvedec
- Department of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Peter Covens
- Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| |
Collapse
|
7
|
Albakri AA, Alzahrani MM, Alghamdi SH. Medical Imaging in Pregnancy: Safety, Appropriate Utilization, and Alternative Modalities for Imaging Pregnant Patients. Cureus 2024; 16:e54346. [PMID: 38500900 PMCID: PMC10945608 DOI: 10.7759/cureus.54346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/11/2024] [Indexed: 03/20/2024] Open
Abstract
This article reviews the existing literature on diagnostic and medical imaging of pregnant women, the risks and safety measures of different medical imaging modalities, and alternative modalities for imaging pregnant patients. Different medical imaging modalities such as MRI, CT scan, ultrasound, nuclear medicine, and X-ray imaging help to evaluate women with recognized or unrecognized pregnancies and identify any underlying complications among pregnant patients. Fetuses are more sensitive to radiation and the effects of medical imaging as compared to adults since they have a rapidly developing cell system. During cell proliferation, migration, and differentiation, fetuses suffer greatly from imaging radiation since they are developing under a dynamic system. To ensure safety, pregnant women should discuss the benefits and risks of medical imaging with their physicians. In addition, radiologists should not perform any medical imaging procedure without the patient's consent, unless the patient cannot make any sound decision. Fetal risks of medical imaging include slow growth and development of the fetus, abortion, malformations, impaired brain function, abnormal childhood growth, and neurological development. Diagnostic imaging procedures are necessary when a condition that needs medical evaluation arises during pregnancy such as appendicitis.
Collapse
Affiliation(s)
| | | | - Saeed H Alghamdi
- Interventional Radiology, King Fahad General Hospital, Al Baha, SAU
| |
Collapse
|
8
|
Stendardo G, Nuccetelli C, Grande S, Palma A, Venoso G, Zicari C, Andenna C, Frau G, Bonanno I, Landoni V, Sciuto R, Bruzzaniti V, Cassano B, Iaccarino G, Murtas F, Canzi C, Zito F, Fattibene P. A real-time system to report abnormal events involving staff in a nuclear medicine therapy unit. RADIATION PROTECTION DOSIMETRY 2023; 199:962-969. [PMID: 37225203 DOI: 10.1093/rpd/ncad098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
A system for internal and voluntary reporting of abnormal events in a Nuclear Medicine Therapy Unit is described. This system is based on the Internet of Things and is composed of an application for mobile devices and a wireless network of detectors. The application is addressed to healthcare professionals and is intended to be a user-friendly tool to make the reporting procedure little laborious. The network of detectors allows for a real-time measurement of the dose distribution in the patient's room. The staff was involved in all stages, from the design of the dosimetry system and mobile application up to their final testing. Face-to-face interviews were carried out with 24 operators in different roles in the Unit (radiation protection experts, physicians, physicists, nuclear medicine technicians and nurses). The preliminary results of the interviews and the current state of development of the application and the detection network will be described.
Collapse
Affiliation(s)
| | - Cristina Nuccetelli
- Istituto Superiore di Sanità, National Center for Radiation Protection and Computational Physics, Rome 00161, Italy
| | - Sveva Grande
- Istituto Superiore di Sanità, National Centre for Innovative Technologies in Public Health, Rome 00161, Italy
| | - Alessandra Palma
- Istituto Superiore di Sanità, National Centre for Innovative Technologies in Public Health, Rome 00161, Italy
| | - Gennaro Venoso
- Istituto Superiore di Sanità, National Center for Radiation Protection and Computational Physics, Rome 00161, Italy
| | - Carmine Zicari
- National Institute for Insurance against Accidents at Work, Department of Technological Innovations and Safety of Plants, Products and Anthropics settlements, Rome 00153, Italy
| | - Claudio Andenna
- National Institute for Insurance against Accidents at Work, Department of Technological Innovations and Safety of Plants, Products and Anthropics settlements, Rome 00153, Italy
| | | | | | - Valeria Landoni
- IRCCS Regina Elena National Cancer Institute, Department of research and advanced technology, Rome 00144, Italy
| | - Rosa Sciuto
- IRCCS Regina Elena National Cancer Institute, Department of research and advanced technology, Rome 00144, Italy
| | - Vicente Bruzzaniti
- IRCCS Regina Elena National Cancer Institute, Department of research and advanced technology, Rome 00144, Italy
| | - Bartolomeo Cassano
- IRCCS Regina Elena National Cancer Institute, Department of research and advanced technology, Rome 00144, Italy
| | - Giuseppe Iaccarino
- IRCCS Regina Elena National Cancer Institute, Department of research and advanced technology, Rome 00144, Italy
| | - Federica Murtas
- IRCCS Regina Elena National Cancer Institute, Department of research and advanced technology, Rome 00144, Italy
| | - Cristina Canzi
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy
| | - Felicia Zito
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan 20122, Italy
| | - Paola Fattibene
- Istituto Superiore di Sanità, Core Facilities, Rome 00161, Italy
| |
Collapse
|
9
|
Béret M, Barry F, Garcia-Fernandez MJ, Chijcheapaza-Flores H, Blanchemain N, Chai F, Nicot R. Efficacy of Intra-Articular Injection of Botulinum Toxin Type A (IncobotulinumtoxinA) in Temporomandibular Joint Osteoarthritis: A Three-Arm Controlled Trial in Rats. Toxins (Basel) 2023; 15:toxins15040261. [PMID: 37104199 PMCID: PMC10142654 DOI: 10.3390/toxins15040261] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Revised: 03/27/2023] [Accepted: 03/28/2023] [Indexed: 04/05/2023] Open
Abstract
Temporomandibular disorders (TMD) are complex pathologies responsible for chronic orofacial pain. Intramuscular injection of botulinum toxin A (BoNT/A) has shown effectiveness in knee and shoulder osteoarthritis, as well as in some TMDs such as masticatory myofascial pain, but its use remains controversial. This study aimed to evaluate the effect of intra-articular BoNT/A injection in an animal model of temporomandibular joint osteoarthritis. A rat model of temporomandibular osteoarthritis was used to compare the effects of intra-articular injection of BoNT/A, placebo (saline), and hyaluronic acid (HA). Efficacy was compared by pain assessment (head withdrawal test), histological analysis, and imaging performed in each group at different time points until day 30. Compared with the rats receiving placebo, those receiving intra-articular BoNT/A and HA had a significant decrease in pain at day 14. The analgesic effect of BoNT/A was evident as early as day 7, and lasted until day 21. Histological and radiographic analyses showed decrease in joint inflammation in the BoNT/A and HA groups. The osteoarthritis histological score at day 30 was significantly lower in the BoNT/A group than in the other two groups (p = 0.016). Intra-articular injection of BoNT/A appeared to reduce pain and inflammation in experimentally induced temporomandibular osteoarthritis in rats.
Collapse
Affiliation(s)
- Marie Béret
- Univ. Lille, INSERM, U1008-Advanced Drug Delivery Systems, F59000 Lille, France
| | - Florent Barry
- Univ. Lille, CHU Lille, INSERM, Department of Oral and Maxillofacial Surgery, U1008-Advanced Drug Delivery Systems, F59000 Lille, France
| | | | | | - Nicolas Blanchemain
- Univ. Lille, INSERM, U1008-Advanced Drug Delivery Systems, F59000 Lille, France
| | - Feng Chai
- Univ. Lille, INSERM, U1008-Advanced Drug Delivery Systems, F59000 Lille, France
| | - Romain Nicot
- Univ. Lille, CHU Lille, INSERM, Department of Oral and Maxillofacial Surgery, U1008-Advanced Drug Delivery Systems, F59000 Lille, France
| |
Collapse
|
10
|
Cunha L, Baete K, Leijen C, Jamar F. Main challenges in radiation protection with emerging radionuclide therapies. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF... 2023; 67:14-28. [PMID: 36598760 DOI: 10.23736/s1824-4785.22.03502-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The recent development of radionuclide therapy and radioligand therapy has raised a call for achieving the highest quality standards, for either radiopharmacy or radiation protection. Novel radionuclides are now being used, either under the form of in-house production radiopharmaceuticals or available from companies. Over the last 20 years, they include radiolabeled microspheres for selective internal radiotherapy (SIRT), the introduction of the first commercially available alpha emitter radiopharmaceutical, 223Ra, and the radiosynoviorthesis which is highly variable across Europe. More important is the development of radioligand therapy, often called theranostics. In this concept, a diagnostic radiopharmaceutical can determine the chance of success of a therapeutic one. Typically, diagnostic radiopharmaceuticals for positron emission tomography, are labeled with 18F or 68Ga, such as the PSMA ligands or somatostatin analogs, and the therapeutic radiopharmaceutical is labeled with 177Lu. This has revolutionized the world of Nuclear Medicine, but also all concepts that shall be applied to properly apply quality assurance and radiation protection in the field. This article will follow the example of 131I as the main used radionuclide for therapy during the last 80 years. Proposals can be general, and in parallel expert's articles will give specific guidance on issues with particular radionuclides, i.e., alpha emitters and 177Lu. This article will also give insight in the radiation protection issues related to the use of microspheres radiolabeled with either 90Y or 166Ho.
Collapse
Affiliation(s)
- Lidia Cunha
- Department of Nuclear Medicine and Molecular Imaging, IsoPor-Azores, Azores, Portugal
| | - Kristof Baete
- Department of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.,Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University of Leuven, Leuven, Belgium
| | - Carolien Leijen
- Department of Radiation Protection, University Medical Center Utrecht, Utrecht, the Netherlands
| | - François Jamar
- Department of Nuclear Medicine, Saint-Luc University Clinic and Institute of Clinical and Experimental Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium -
| |
Collapse
|
11
|
Jamar F, Cunha L. Radiation protection issues with novel radionuclide therapies: a real challenge. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF... 2023; 67:1-3. [PMID: 36630082 DOI: 10.23736/s1824-4785.22.03505-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- François Jamar
- Department of Nuclear Medicine, Saint-Luc University Hospital and Institute of Clinical and Experimental Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium -
| | - Lidia Cunha
- Department of Nuclear Medicine and Molecular Imaging, IsoPor-Azores, Azores, Portugal
| |
Collapse
|
12
|
Craig AJ, Taprogge J, Flux GD, Murray I. Radiation protection aspects for alpha therapies. THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF... 2023; 67:4-13. [PMID: 36633588 DOI: 10.23736/s1824-4785.22.03501-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
The use of alpha emitting radiotherapeutics is increasing, with further growth expected due to a number of clinical trials currently running involving new alpha emitters. However, literature concerning radiation safety aspects of alpha emitting radionuclides is limited and most of the available literature concerns 223Ra. In general, the occupational exposure from alpha emitting radionuclides is expected to be low, as are doses to the public from external exposure. However, care must be taken to avoid skin contamination, inhalation, and ingestion. Not all alpha emitting radionuclides are identical, they often have very different associated decay chains and emissions. The decay chains and the manufacturing process should be carefully examined to identify any long-lived progeny or impurities. These may have an impact on the radiation safety processes required to limit occupational exposure and for waste management. Doses to the public must also be assessed, either arising directly from exposure to patients treated with radiotherapeutics, or via waste streams. Risk assessments should be in place when starting a new service covering all aspects of the preparation and administration, as well as any foreseeable incidents such as skin contamination or patient death, and the appropriate steps to take in these instances. It is imperative that with the increase in the use of alpha emitting radiotherapeutics more literature is published on radiation safety aspects, especially for new alpha emitting radiotherapeutics which often have very different characteristics than the currently established ones.
Collapse
Affiliation(s)
- Allison J Craig
- Joint Department of Physics, Royal Marsden NHSFT, Sutton, UK - .,The Institute of Cancer Research, London, UK -
| | - Jan Taprogge
- Joint Department of Physics, Royal Marsden NHSFT, Sutton, UK.,The Institute of Cancer Research, London, UK
| | - Glenn D Flux
- Joint Department of Physics, Royal Marsden NHSFT, Sutton, UK.,The Institute of Cancer Research, London, UK
| | - Iain Murray
- Joint Department of Physics, Royal Marsden NHSFT, Sutton, UK.,The Institute of Cancer Research, London, UK
| |
Collapse
|
13
|
Donzé C, Rubira L, Santoro L, Kotzki PO, Deshayes E, Fersing C. Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals Administration. Healthcare (Basel) 2022; 10:2247. [PMID: 36360590 PMCID: PMC9690994 DOI: 10.3390/healthcare10112247] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 11/04/2022] [Accepted: 11/07/2022] [Indexed: 06/21/2024] Open
Abstract
Securing both the patient and radiopharmaceuticals (RPs) circuit is an essential concern in nuclear medicine (NM). These circuits converge at the RP administration phase, a key step in patient management in NM. In a continuous quality improvement approach, we developed and implemented an evaluation of professional practices (EPPs) methodology focused on RPs injection to identify and correct deviations from good practices. The nuclear medicine technologists (NMTs) of a single center were evaluated. A specific audit grid was designed for this purpose, covering 4 main themes. Following the audit campaign, an improvement action plan was set up to address the non-conformities observed. Nine NMTs were audited on 4 RPs injections each. The mean total score was 93.36% with, on average, 7.01% and 3.00% of unmet and partially met criteria, respectively. In view of the non-compliance rates of hygiene and radiation protection items, theoretical reviews of these themes were included in the improvement action plan. As a part of the quality assurance system of a healthcare unit, EPPs are useful for identifying and correcting practice deviations at an early stage. They should be regularly repeated and combined with rigorous training and qualification of operators involved in RPs injection.
Collapse
Affiliation(s)
- Charlotte Donzé
- Nuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France
| | - Léa Rubira
- Nuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France
| | - Lore Santoro
- Nuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France
| | - Pierre Olivier Kotzki
- Nuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France
| | - Emmanuel Deshayes
- Nuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France
- Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut Régional du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France
| | - Cyril Fersing
- Nuclear Medicine Department, Institut Régional du Cancer de Montpellier (ICM), University Montpellier, 34298 Montpellier, France
- IBMM, University Montpellier, CNRS, ENSCM, 34293 Montpellier, France
| |
Collapse
|
14
|
Marengo M, Infantino A. Assessment of emission data and transmission factors supporting radiation protection in the use of 225Ac. Phys Med 2022; 103:59-65. [DOI: 10.1016/j.ejmp.2022.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 10/03/2022] [Accepted: 10/07/2022] [Indexed: 11/29/2022] Open
|
15
|
Ohnuki K, Yoshimoto M, Haba H, Manabe S, Takashima H, Yasunaga M, Takenaka Y, Fujii H. Protection from contamination by 211At, an enigmatic but promising alpha-particle-emitting radionuclide. EJNMMI Phys 2022; 9:39. [PMID: 35666329 PMCID: PMC9167904 DOI: 10.1186/s40658-022-00469-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Accepted: 05/19/2022] [Indexed: 01/08/2023] Open
Abstract
Purpose 211At, a promising alpha-particle-emitting radionuclide, can easily volatilize and contaminate the environment. To safely manage this unique alpha-particle-emitting radionuclide, we investigated the permeability of four types of plastic films and two types of rubber gloves against 211At and identified suitable materials that prevent contamination by 211At. Methods Four types of plastic films, polyethylene, polyvinylidene chloride, polyvinyl chloride, and a laminated film, and two types of rubber gloves, latex and nitrile, were examined. Small pieces of filter paper were covered with these materials, and a drop containing 100 kBq of 211At was placed on them. The radioactivity of the pieces of filter paper under the materials was evaluated by measuring counts using a gamma counter and obtaining autoradiograms 3.5 h later. These experiments were also performed using 225Ac, 125I, 111In, 201Tl, and 99mTc. Results 211At solution easily penetrated polyethylene, polyvinyl chloride, and latex rubber. Similar results were obtained for 125I, while other radionuclides did not penetrate films or gloves. These results suggest that halogenic radionuclides under anionic conditions are likely to penetrate plastic films and rubber gloves. Conclusion Our evaluation revealed that, when 211At solution is used, the protection by polyvinylidene chloride, a laminated film, or nitrile rubber would be more effective than that by polyethylene, polyvinyl chloride, or latex rubber. Supplementary Information The online version contains supplementary material available at 10.1186/s40658-022-00469-9.
Collapse
Affiliation(s)
- Kazunobu Ohnuki
- Division of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan
| | - Mitsuyoshi Yoshimoto
- Division of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan
| | - Shino Manabe
- Pharmaceutical Department, Hoshi University, 2-4-41, Ebara, Shinagawa, Tokyo, 142-8501, Japan.,Research Center for Pharmaceutical Development, Graduate School of Pharmaceutical Sciences and Faculty of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai, 980-8578, Japan
| | - Hiroki Takashima
- Division of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan
| | - Masahiro Yasunaga
- Division of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan
| | - Yasumasa Takenaka
- RIKEN Center for Sustainable Resource Science, Bioplastic Research Team, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan
| | - Hirofumi Fujii
- Division of Functional Imaging, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.
| |
Collapse
|
16
|
Jecong J, Hila F, Balderas C, Guillermo N. Effect of the new photoatomic data library EPDL2017 to mass attenuation coefficient calculation of materials used in the nuclear medicine facilities using EpiXS software. NUCLEAR ENGINEERING AND TECHNOLOGY 2022. [DOI: 10.1016/j.net.2022.03.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Sathekge MM, Bouchelouche K. Letter from the Editors. Semin Nucl Med 2022; 52:91-93. [DOI: 10.1053/j.semnuclmed.2022.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|